[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 26 of about 26
1. Bakrac M, Bonaci-Nikolić B, Colović N, Simić-Ogrizović S, Krstić M, Colović M: [Enteropathy associated T-cell lymphoma]. Srp Arh Celok Lek; 2007 Jan-Feb;135(1-2):80-4
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Enteropathy associated T-cell lymphoma].
  • Enteropathy associated T-cell lymphoma (EATCL) is a high grade, pleomorphic peripheral T-cell lymphoma with usually cytotoxic phenotype.
  • Diagnosis of lymphoma was confirmed after the resection of the jejunum (small intestine obstruction).
  • Pathohistological (PAS, Reticulin, Giemsa) and immunohistochemical (anti-LCA, anti-CD20, anti-CD45RO, anti-CD3) methods revealed the diagnosis of EATCL: CD45RO+, CD3+.
  • After the third cycle of chemotherapy, the disease progressed with massive lung infiltration.
  • According to established diagnosis of tubulointerstitial nephritis, she was treated with pulse doses of steroid therapy.
  • On MRI, small intestinal wall was thickened, and abdominal lymph nodes were enlarged with extraluminal compression of common bile duct.
  • Laparotomy with mesenterial lymph node biopsy and consecutive pathohistological and immunohistochemical analyses revealed the diagnosis of EATCL.
  • The patient received chemotherapy, but she died with signs of pulmonary embolization.
  • Diagnosis of EATCL was revealed after the resection of jejunum because of small intestinal obstruction.
  • She received two cycles of chemotherapy, but she died with signs of disease progression.
  • The overall survival of patients was 7 months.The possibility of lymphoma rising in patients with clinical progression of GSE despite gluten free diet must be kept in mind.
  • [MeSH-major] Celiac Disease / complications. Intestinal Neoplasms / complications. Lymphoma, T-Cell, Peripheral / complications

  • Genetic Alliance. consumer health - Enteropathy-Associated T-Cell Lymphoma.
  • MedlinePlus Health Information. consumer health - Celiac Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17503573.001).
  • [ISSN] 0370-8179
  • [Journal-full-title] Srpski arhiv za celokupno lekarstvo
  • [ISO-abbreviation] Srp Arh Celok Lek
  • [Language] srp
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Serbia and Montenegro
  •  go-up   go-down


2. Okuda M, Nomura J, Tateno H, Kameoka J, Sasaki T: CD56 positive intestinal T-cell lymphoma: treatment with high dose chemotherapy and autologous peripheral blood stem cell transplantation. Intern Med; 2002 Sep;41(9):734-7
Genetic Alliance. consumer health - Transplantation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CD56 positive intestinal T-cell lymphoma: treatment with high dose chemotherapy and autologous peripheral blood stem cell transplantation.
  • A 63-year-old man presented with a perforation of the small intestine.
  • A diagnosis of intestinal T-cell lymphoma (ITCL) was made from CD (cluster differentiation) 3 positivity and a rearrangement of T-cell receptor genes.
  • Although the prognosis of ITCL has been considered to be very poor irrespective of CD56 positivity, complete remission was achieved in this case by high dose chemotherapy followed by autologous peripheral blood stem cell transplantation (auto-PBSCT) even after relapse.
  • [MeSH-major] Antigens, CD56 / metabolism. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Intestinal Neoplasms / therapy. Lymphoma, T-Cell / therapy. Peripheral Blood Stem Cell Transplantation / methods
  • [MeSH-minor] Combined Modality Therapy. Humans. Intestinal Perforation / pathology. Intestinal Perforation / radiography. Intestinal Perforation / surgery. Male. Middle Aged. Remission Induction / methods. Tomography, X-Ray Computed. Transplantation, Autologous. Treatment Outcome

  • Genetic Alliance. consumer health - Peripheral T-cell lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12322803.001).
  • [ISSN] 0918-2918
  • [Journal-full-title] Internal medicine (Tokyo, Japan)
  • [ISO-abbreviation] Intern. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antigens, CD56
  •  go-up   go-down


3. Takahashi T, Maruyama R, Mishima S, Inoue M, Kawakami K, Onishi C, Miyake T, Tanaka J, Nabika T, Ishikura H: Small bowel perforation caused by Epstein-Barr virus-associated B cell lymphoma in a patient with angioimmunoblastic T-cell lymphoma. J Clin Exp Hematop; 2010;50(1):59-63

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Small bowel perforation caused by Epstein-Barr virus-associated B cell lymphoma in a patient with angioimmunoblastic T-cell lymphoma.
  • On rare occasions, secondary Epstein-Barr virus (EBV)-associated B cell lymphoma can develop in a patient with angioimmunoblastic T-cell lymphoma (AITL).
  • We report a case of a 66-year-old Japanese woman who developed diffuse large B-cell lymphoma (DLBCL) in her small intestine after chemotherapy for AITL.
  • She was found to have panperitonitis due to perforation of the small intestine.
  • Partial ileectomy specimen showed DLBCL cells infiltrating into the intestinal wall.
  • In situ hybridization for EBV-encoded RNA revealed positivity in the lymphoma cells.
  • The lymph nodes diagnosed as AITL were negative for EBV infection and there was no coexistence of B cell neoplasms in them.
  • We thought small bowel perforation in this case was caused by EBV-associated B cell lymphoma secondary to AITL.
  • Our case showed a remarkable deficiency of cellular immunity after chemotherapy, which we postulate was related to the cause of occurrence of B-cell lymphoma.
  • [MeSH-major] Epstein-Barr Virus Infections / complications. Intestinal Neoplasms / complications. Intestinal Perforation / etiology. Lymphoma, Large B-Cell, Diffuse / complications. Lymphoma, T-Cell / complications

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20505277.001).
  • [ISSN] 1880-9952
  • [Journal-full-title] Journal of clinical and experimental hematopathology : JCEH
  • [ISO-abbreviation] J Clin Exp Hematop
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


Advertisement
4. Ahn MJ, Park YW, Han D, Choi JH, Shin SJ, Yoon BC, Choi HS, Lee YY, Jung TJ, Choi IY, Park MH, Kim IS: A case of primary intestinal T-cell lymphoma involving entire gastrointestinal tract: esophagus to rectum. Korean J Intern Med; 2000 Dec;15(3):245-9
MedlinePlus Health Information. consumer health - Esophageal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of primary intestinal T-cell lymphoma involving entire gastrointestinal tract: esophagus to rectum.
  • Primary intestinal T-cell lymphoma is a rare disease entity, which is approximately 10% to 25% of intestinal lymphomas, and most of the lymphomas occur in the small intestine.
  • Abdominal CT scan and small bowel series showed diffuse wall thickening of the small bowel.
  • Gastroscopic examination showed diffuse erythematous lesions on the esophagus and small gastric ulcerations on the antrum of the stomach, and colonoscopic examination also showed multiple punched-out ulcerations and erosions on the entire colon, including the sigmoid colon to the terminal ileum.
  • Diffuse infiltration of CD 3 positive lymphoma cells was found on biopsy.
  • The patient was diagnosed as primary intestinal T-cell lymphoma with diffuse involvement of the entire gastrointestinal tracts from the esophagus to the rectum.
  • Although the patient received systemic combination chemotherapy and achieved partial response initially, the lymphoma relapsed repeatedly.
  • [MeSH-major] Esophageal Neoplasms / therapy. Gastrointestinal Neoplasms / therapy. Lymphoma, T-Cell / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11242815.001).
  • [ISSN] 1226-3303
  • [Journal-full-title] The Korean journal of internal medicine
  • [ISO-abbreviation] Korean J. Intern. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC4531775
  •  go-up   go-down


5. Alzubi A, Zöllei I, Krenács L, Intzédy K, Hudák J: [Primary T-cell lymphoma of the small bowel]. Magy Seb; 2008 Apr;61(2):79-83
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Primary T-cell lymphoma of the small bowel].
  • [Transliterated title] Primer vékonybél T-sejtes lymphoma operált esete.
  • Primary malignancies in the small intestine are relatively rare.
  • The authors report a case of a primary T-cell lymphoma in the small bowel that caused diagnostic challenges.
  • Blood tests, endoscopic examinations, ultrasonography and CT scan could not reveal a definitive diagnosis.
  • While a small bowel follow through examination demonstrated an entero-enteral fistula, its exact position could not have been determined.
  • Consequently, an exploratory laparotomy was carried out, and a tumour was found involving the small bowel loops.
  • The involved portion of the small intestine (with the fistula) was resected, and a side-to-side small bowel anastomosis was performed.
  • Histological and immunohistochemical analyses revealed a primary T-cell lymphoma of the small bowel.
  • There was no evidence of metastatic disease at the time of surgery.
  • The patient received adjuvant chemotherapy, but three months later multiple lung metastases were detected.
  • Small bowel malignant tumours cause significant diagnostic difficulties.
  • Therefore, diagnosis and adequate treatment are usually delayed for some weeks.
  • Nevertheless, surgical exploration and resection of the tumour will be necessary for the correct diagnosis and treatment.
  • [MeSH-major] Intestinal Neoplasms / diagnosis. Intestinal Neoplasms / surgery. Intestine, Small / pathology. Lung Neoplasms / secondary. Lymphoma, T-Cell / diagnosis. Lymphoma, T-Cell / surgery
  • [MeSH-minor] Aged. Anastomosis, Surgical. Chemotherapy, Adjuvant. Diagnosis, Differential. Female. Humans. Intestinal Fistula / diagnosis. Intestinal Fistula / surgery. Laparotomy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18426712.001).
  • [ISSN] 0025-0295
  • [Journal-full-title] Magyar sebészet
  • [ISO-abbreviation] Magy Seb
  • [Language] hun
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Hungary
  •  go-up   go-down


6. Nomura K, Tomikashi K, Matsumoto Y, Yoshida N, Okuda T, Sakakura C, Mitsufuji S, Horiike S, Yamagishi H, Okanoue T, Taniwaki M: Small bowel non-Hodgkin's lymphoma remaining in complete remission by surgical resection and adjuvant rituximab therapy. World J Gastroenterol; 2005 Jul 28;11(28):4443-4
Hazardous Substances Data Bank. RITUXIMAB .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Small bowel non-Hodgkin's lymphoma remaining in complete remission by surgical resection and adjuvant rituximab therapy.
  • Because distention of fluid- and gas-filled loops of small intestine was proved by X-ray, the patient was diagnosed as having small bowel obstruction.
  • A laparotomy revealed a segmental stenosis in the jejunum, which showed diffuse thickening of the intestinal wall.
  • We diagnosed diffuse large B-cell lymphoma based on the pathological findings of diffuse transmural infiltration of large lymphoid cells and flow-cytometric analyses.
  • Rituximab was administered as adjuvant therapy at weekly doses of 375 mg/m2.
  • Rituximab may be effective as adjuvant therapy.
  • [MeSH-major] Antibodies, Monoclonal / administration & dosage. Antineoplastic Agents / administration & dosage. Intestinal Neoplasms / drug therapy. Intestinal Neoplasms / surgery. Lymphoma, Non-Hodgkin / drug therapy. Lymphoma, Non-Hodgkin / surgery
  • [MeSH-minor] Adult. Antibodies, Monoclonal, Murine-Derived. Combined Modality Therapy. Humans. Male. Remission Induction. Rituximab

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16038051.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antineoplastic Agents; 4F4X42SYQ6 / Rituximab
  • [Other-IDs] NLM/ PMC4434679
  •  go-up   go-down


7. Tokuhira M, Watanabe R, Iizuka A, Sekiguchi Y, Nemoto T, Hanzawa K, Takamatsu I, Maruyama T, Tamaru J, Itoyama S, Suzuki H, Takeuchi T, Mori S: De novo CD5+ diffuse large B cell lymphoma with basophilia in the peripheral blood: successful treatment with autologous peripheral blood stem cell transplantation. Am J Hematol; 2007 Feb;82(2):162-7
Genetic Alliance. consumer health - Transplantation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] De novo CD5+ diffuse large B cell lymphoma with basophilia in the peripheral blood: successful treatment with autologous peripheral blood stem cell transplantation.
  • Here, we report the case of a 33-year-old man with a bulky mass of the small intestine, multiple paraaortic lymphoadenopathy, pleural effusion, and ascites, who was diagnosed as a case of de novo CD5+ diffuse large B cell lymphoma (DLBCL).
  • High dose chemotherapy followed by autologous peripheral blood cell transplantation yielded complete remission, and the patient has remained disease free for 5 years.
  • [MeSH-major] Antigens, CD5. Basophils. Intestinal Neoplasms / therapy. Lymphoma, B-Cell / therapy. Lymphoma, Large B-Cell, Diffuse / therapy. Peripheral Blood Stem Cell Transplantation. Pleural Effusion, Malignant / therapy
  • [MeSH-minor] Adult. Ascites / blood. Ascites / pathology. Ascites / radiography. Ascites / therapy. Asian Continental Ancestry Group. Humans. Japan. Male. Remission Induction. Transplantation, Autologous. Tumor Burden

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2006 Wiley-Liss, Inc.
  • (PMID = 17019691.001).
  • [ISSN] 0361-8609
  • [Journal-full-title] American journal of hematology
  • [ISO-abbreviation] Am. J. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD5
  •  go-up   go-down


8. Carreras JK, Goldschmidt M, Lamb M, McLear RC, Drobatz KJ, Sørenmo KU: Feline epitheliotropic intestinal malignant lymphoma: 10 cases (1997-2000). J Vet Intern Med; 2003 May-Jun;17(3):326-31
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Feline epitheliotropic intestinal malignant lymphoma: 10 cases (1997-2000).
  • The clinical, histopathologic, and immunohistochemical features of 10 cats with epitheliotropic intestinal malignant lymphoma (EIL) are described.
  • Intestinal biopsy samples were reviewed by 3 pathologists to confirm the diagnosis of EIL.
  • These samples (n = 10) were compared to the intestinal biopsies of normal cats (n = 11), cats with inflammatory bowel disease (IBD; n = 7), and cats with non-EIL (n = 9) for quantification and immunophenotyping of intraepithelial lymphocytes.
  • Immunophenotypic studies were performed with CD3 and CD79a antibody stains to assess for T- and B-cell immunoreactivity, respectively.
  • EIL biopsies had markedly more intraepithelial lymphocytes than normal intestine (NRL) and samples from cats with IBD.
  • Regardless of the histologic diagnosis, the intraepithelial lymphocytes in all cats were small- to intermediate-sized T cells.
  • Most cats fit the typical profile of cats with IBD or alimentary malignant lymphoma.
  • Nine of 10 cats with EIL were treated with prednisone with or without additional chemotherapy.
  • Four cats were refractory to chemotherapy and were euthanized within 3.5 months.
  • The remaining 5 cats had long-term survival times of 11 months or greater.
  • The median survival time was 11 months.
  • Additional studies are warranted to better characterize EIL and its relationship to IBD in cats and non-EIL and to identify optimal treatment strategies for this disease.

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12774974.001).
  • [ISSN] 0891-6640
  • [Journal-full-title] Journal of veterinary internal medicine
  • [ISO-abbreviation] J. Vet. Intern. Med.
  • [Language] ENG
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


9. Kataoka I, Arima F, Nishimoto J, Watanabe T, Kobayashi Y, Tamura R, Yamamoto S, Matsuno Y, Shimoda T, Tobinai K: Enteropathy-type T-cell lymphoma showing repeated small bowel rupture and refractoriness to chemotherapy: a case report. Jpn J Clin Oncol; 2002 Dec;32(12):546-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Enteropathy-type T-cell lymphoma showing repeated small bowel rupture and refractoriness to chemotherapy: a case report.
  • The majority of gastrointestinal lymphomas arise in the stomach, whereas lymphomas occurring in the intestine are relatively rare and a limited fraction of them show the T-cell phenotype with clinical manifestations similar to de novo celiac disease.
  • Enteropathy-type T-cell lymphoma is extremely rare in Japan, presumably owing to the very low incidence of celiac disease among the Japanese population.
  • Here, we report a 66-year-old Japanese male who was diagnosed as having enteropathy-type T-cell lymphoma preceded by diarrhea and intermittent bloody stool for over 1 year.
  • He was admitted to our hospital as an emergency case because of panperitonitis due to intestinal perforation.
  • After immediate partial small-bowel resection, cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) chemotherapy was started.
  • Subsequent salvage chemotherapy could not be completed because of the formation of spontaneous jejuno-abdominal fistula, followed by fatal septic shock.
  • Particular attention should be paid to the peculiar clinical manifestations of enteropathy-type T-cell lymphoma such as malnutrition, frequent intestinal perforation and refractoriness to chemotherapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Intestinal Fistula / etiology. Intestinal Neoplasms / drug therapy. Intestinal Perforation / etiology. Jejunal Diseases / etiology. Lymphoma, T-Cell / drug therapy

  • MedlinePlus Health Information. consumer health - Small Intestine Disorders.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12578905.001).
  • [ISSN] 0368-2811
  • [Journal-full-title] Japanese journal of clinical oncology
  • [ISO-abbreviation] Jpn. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol; EPOCH protocol
  •  go-up   go-down


10. Brueck M, Barton M, Rauber K, Zikova A, Kramer W: [Ileus of the small intestine in intestinal marginal-zone B-cell lymphoma of mucoid-associated lymphoid tissue (MALT)]. Dtsch Med Wochenschr; 2001 Dec 7;126(49):1391-5
MedlinePlus Health Information. consumer health - Small Intestine Disorders.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Ileus of the small intestine in intestinal marginal-zone B-cell lymphoma of mucoid-associated lymphoid tissue (MALT)].
  • [Transliterated title] Dünndarmileus bei intestinalem Marginalzonen-B-Zell-Lymphom des MALT.
  • The X-ray showed ileus of the small intestine which required emergency laparotomy.
  • It was removed by partial resection of the small intestine.
  • DIAGNOSIS: Ileus of the small intestine with a low-malignant marginal zone B-cell (non-Hodgkin) lymphoma of MALT type (mucoid-associated lymphoid tissue).
  • TREATMENT AND COURSE: Postoperative staging indicated no further manifestation of the lymphoma.
  • As no radical operation in resecting the tumour had been performed, combined radio- and chemotherapy was undertaken.
  • CONCLUSION: Marginal B-cell lymphomas of the small intestine are only rarely seen in central Europe.
  • Despite its usually slow growth this non-Hodgkin lymphoma of low malignancy can produce an acute mechanical ileus without prodromal symptoms.
  • A multimodal therapeutic approach is often employed, but there are no established treatment strategies.
  • [MeSH-major] Ileal Diseases / etiology. Intestinal Neoplasms / diagnosis. Intestinal Obstruction / etiology. Lymphoma, B-Cell, Marginal Zone / diagnosis

  • MedlinePlus Health Information. consumer health - Intestinal Obstruction.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11740631.001).
  • [ISSN] 0012-0472
  • [Journal-full-title] Deutsche medizinische Wochenschrift (1946)
  • [ISO-abbreviation] Dtsch. Med. Wochenschr.
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


11. Nava VE, Cohen P, Bishop M, Fowler D, Jaffe ES, Ozdemirli M: Enteropathy-type T-cell lymphoma after intestinal diffuse large B-cell lymphoma. Am J Surg Pathol; 2007 Mar;31(3):476-80
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Enteropathy-type T-cell lymphoma after intestinal diffuse large B-cell lymphoma.
  • A rare case of enteropathy-type T-cell lymphoma (ETL) developed in a 47-year-old Chinese male 6 years after the diagnosis of diffuse large B-cell lymphoma (DLBCL) in the small intestine.
  • Work-up demonstrated an ulcerated mass in the small intestine.
  • Partial resection and histologic examination of the intestine showed a DLBCL, positive for CD20 and Bcl-2, involving the jejunum transmurally.
  • The patient was treated aggressively with radiotherapy, chemotherapy, and autologous bone marrow transplant, and complete remission was obtained.
  • Clinical work-up revealed thickening of the small intestinal wall, and biopsies demonstrated ETL based on morphology, immunohistochemistry, and polymerase chain reaction analysis.
  • The patient responded to chemotherapy, received allogeneic peripheral blood stem cell transplantation from an HLA-matched sibling donor, and remains in remission.
  • Possible associations between the 2 types of lymphoma are discussed.
  • [MeSH-major] Intestinal Neoplasms / pathology. Lymphoma, B-Cell / pathology. Lymphoma, Large B-Cell, Diffuse / pathology. Lymphoma, T-Cell / pathology. Neoplasms, Second Primary / pathology
  • [MeSH-minor] Adult. Biomarkers, Tumor / analysis. Celiac Disease / complications. Celiac Disease / diagnosis. Chemotherapy, Adjuvant. Humans. Immunohistochemistry. Male. Neoplasm Staging. Peripheral Blood Stem Cell Transplantation. Treatment Outcome

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17325491.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


12. Nakamura S, Matsumoto T, Iida M: [Malignant lymphoma of the small intestine]. Nihon Rinsho; 2008 Jul;66(7):1297-302
MedlinePlus Health Information. consumer health - Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Malignant lymphoma of the small intestine].
  • The clinicopathologic features of malignant lymphoma of the small intestine were reviewed.
  • Genetically, characteristic chromosomal translocations have been identified in several B-cell lymphomas, such as t (11 ; 18)/API2-MALT1 in MALT lymphoma, t (14 ; 18)/IGH-BCL2 in follicular lymphoma, or t (3 ; 14)/BCL6-IGH in diffuse large B-cell lymphoma (DLBCL).
  • Histologically, DLBCL is most frequently observed, and T-cell lymphoma and follicular lymphoma are more frequent in small intestinal cases than in gastric cases.
  • Macroscopically, small intestinal lymphomas are classified as polypoid, ulcerative (including stricturing, non-stricturing and aneurysmal forms on radiography), multiple lymphomatous polyposis, diffuse, or other types.
  • A significant correlation is observed between these macroscopic/radiographic and histologic types.
  • The therapeutic strategy, such as surgery, chemotherapy, antibiotics or watch-and-wait, should be determined based on the disease extent, histologic type, and clinical stage.
  • [MeSH-major] Intestinal Neoplasms. Intestine, Small. Lymphoma

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18616120.001).
  • [ISSN] 0047-1852
  • [Journal-full-title] Nihon rinsho. Japanese journal of clinical medicine
  • [ISO-abbreviation] Nippon Rinsho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 13
  •  go-up   go-down


13. Huang GT, Zhu GH: [Experience of the diagnosis and treatment of primary small intestine lymphoma]. Zhonghua Wai Ke Za Zhi; 2010 Jan 1;48(1):45-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Experience of the diagnosis and treatment of primary small intestine lymphoma].
  • OBJECTIVE: To report the experiences of the diagnosis and treatment of primary lymphoma of the small intestine (PSIL).
  • Data of gender, age, clinical manifestation, laboratory examination, imageology examination, diagnosis and treatment of the patients was reviewed.
  • All the patients were diagnosed as non-Hodgkin lymphoma (NHL) by postoperative pathology (8 patients as diffuse large B-cell lymphoma, 5 as mucosa associated lymphoid tissue type B cell lymphoma and 2 as enteropathy-type intestinal T cell lymphoma).
  • Ten patients received adjuvant chemotherapy with the regimen of CHOP (cyclophosphamide + epirubicin + vincristine + prednisone) after the operation.
  • Fourteen cases were followed-up for a mean time of 30 months (range, 6 - 52 months).
  • Operation combined with chemotherapy is important for PSIL.
  • [MeSH-major] Intestinal Neoplasms / diagnosis. Intestinal Neoplasms / therapy. Intestine, Small / pathology. Lymphoma / diagnosis. Lymphoma / therapy

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20302754.001).
  • [ISSN] 0529-5815
  • [Journal-full-title] Zhonghua wai ke za zhi [Chinese journal of surgery]
  • [ISO-abbreviation] Zhonghua Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


14. Wakabayashi S, Arai A, Oshikawa G, Araki A, Watanabe M, Uchida N, Taniguchi S, Miura O: Extranodal NK/T cell lymphoma, nasal type, of the small intestine diagnosed by double-balloon endoscopy. Int J Hematol; 2009 Dec;90(5):605-10

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extranodal NK/T cell lymphoma, nasal type, of the small intestine diagnosed by double-balloon endoscopy.
  • Extranodal NK/T-cell lymphoma (ENKL), nasal type, is rare and the small intestine is quite extraordinary as a primary lesion site.
  • We report a 47-year-old man with ENKL of the small intestine.
  • He was referred to our hospital because of bloody stool and the diagnosis was made by double-balloon endoscopy (DBE) of the small intestine without surgical procedure.
  • He went into complete remission (CR) after intensive chemotherapy (DeVIC) and subsequently underwent allogeneic bone marrow transplantation (BMT).
  • Although he remained in CR for about 8 months after BMT, he died of disease recurrence 14 months after the diagnosis was made.
  • ENKL of the small intestine follows a highly aggressive course.
  • We describe the usefulness of DBE for diagnosis and management for ENKL of the small intestine.
  • Additional cases, however, should be accumulated to establish optimal treatment strategy.
  • [MeSH-major] Endoscopy, Gastrointestinal / methods. Intestinal Neoplasms / diagnosis. Lymphoma, Extranodal NK-T-Cell / diagnosis
  • [MeSH-minor] Combined Modality Therapy. Fatal Outcome. Humans. Intestine, Small / pathology. Male. Middle Aged. Nose Neoplasms

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Endoscopy. 2007 Feb;39(2):156-60 [17657701.001]
  • [Cites] Hum Pathol. 2004 May;35(5):639-42 [15138943.001]
  • [Cites] Hematol Oncol. 2008 Jun;26(2):66-72 [18283711.001]
  • [Cites] Eur J Cancer. 2005 Jul;41(10):1402-8 [15963893.001]
  • [Cites] Blood. 2004 Jul 1;104(1):243-9 [15031209.001]
  • [Cites] Blood. 1997 Jun 15;89(12):4501-13 [9192774.001]
  • [Cites] Dig Dis Sci. 2010 Jan;55(1):158-65 [19241169.001]
  • [Cites] Histopathology. 2004 May;44(5):480-9 [15139996.001]
  • [Cites] Rinsho Ketsueki. 1994 Jul;35(7):635-41 [8065017.001]
  • [Cites] J Gastroenterol Hepatol. 2009 May;24(5):770-5 [19220668.001]
  • [Cites] Pathol Int. 2000 Sep;50(9):696-702 [11012982.001]
  • [Cites] Leuk Res. 2004 Apr;28(4):339-43 [15109531.001]
  • [Cites] Cancer. 2001 Feb 1;91(3):525-33 [11169934.001]
  • [Cites] Am J Surg Pathol. 2009 Aug;33(8):1230-40 [19561449.001]
  • [Cites] Ann Oncol. 2008 Aug;19(8):1477-84 [18385201.001]
  • [Cites] J Clin Oncol. 2006 Feb 1;24(4):612-8 [16380410.001]
  • [Cites] Hematology. 2005 Jun;10(3):237-45 [16019472.001]
  • (PMID = 19936878.001).
  • [ISSN] 1865-3774
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


15. Joyce AM, Burns DL, Marcello PW, Tronic B, Scholz FJ: Capsule endoscopy findings in celiac disease associated enteropathy-type intestinal T-cell lymphoma. Endoscopy; 2005 Jun;37(6):594-6
MedlinePlus Health Information. consumer health - Intestinal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Capsule endoscopy findings in celiac disease associated enteropathy-type intestinal T-cell lymphoma.
  • Capsule endoscopy is a new technology developed to investigate diseases of the small intestine.
  • It has been shown to be superior to current modalities such as small-bowel radiography and enteroscopy.
  • The symptom complex and results from small-bowel radiography and computerized tomography raised concern about progression to lymphoma, and ultimately a laparoscopy and small-bowel resection were done for diagnosis.
  • A capsule endoscopy was performed to assess the extent of the patient's enteropathy-type intestinal T-cell lymphoma after three cycles of chemotherapy.
  • We report the first use of capsule endoscopy in the setting of celiac disease associated enteropathy-type intestinal T-cell lymphoma.
  • These endoscopic findings are correlated with those from gross and microscopic pathology and barium small-bowel radiography.
  • [MeSH-major] Celiac Disease / diagnosis. Endoscopy, Digestive System / methods. Jejunal Neoplasms / diagnosis. Lymphoma, T-Cell / diagnosis. Miniaturization / instrumentation
  • [MeSH-minor] Biopsy. Diagnosis, Differential. Humans. Intestinal Mucosa / pathology. Male. Middle Aged. Radiography, Abdominal. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Celiac Disease.
  • MedlinePlus Health Information. consumer health - Celiac Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15933938.001).
  • [ISSN] 0013-726X
  • [Journal-full-title] Endoscopy
  • [ISO-abbreviation] Endoscopy
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


16. Bai CM, Yang T, Xü Y, Zhang W, Liu XL, Zhu YL, Chen SC, Shen T: [Clinical analysis of 32 primary intestinal non-Hodgkin's lymphoma]. Zhonghua Zhong Liu Za Zhi; 2006 Feb;28(2):142-4
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical analysis of 32 primary intestinal non-Hodgkin's lymphoma].
  • OBJECTIVE: To investigate the clinical and pathological features, optimal treatment and prognostic factors in primary intestinal non-Hodgkin's lymphoma.
  • METHODS: The clinical presentations, pathological features and therapeutic results of 32 primary intestinal non-Hodgkin's lymphoma were retrospectively analyzed.
  • RESULTS: The most frequently site of the lesions in the 32 patients was the large intestine (n = 16, 50.0%), followed by small intestine (n = 8, 25.0%), ileocaecal region (n = 6, 18.8%) and multiple intestinal sites (n = 2, 6.2%).
  • Twenty-one patients (65.6%) were diagnosed as B-cell lymphoma, 15 (46.9%) were diffuse large B-cell lymphoma.
  • Ten patients (31.2%) were diagnosed as T-cell lymphoma and one (3.1%) as histiocytic lymphoma.
  • Twenty-nine patients were treated initially by surgery with or without chemotherapy, 19 of them (59.4%) achieved complete response.
  • Based on Cox multivariate analysis, stage III - IV, B symptoms and T cell phenotype of the disease were the independent adverse prognostic factors (P < 0.05).
  • CONCLUSION: The clinical presentation of primary intestinal non-Hodgkin's lymphoma are not specific clinically.
  • Most of the histological types are diffuse large B-cell type lymphoma.
  • Complete resection combined with chemotherapy may be the best effective approach for treatment of this disease.
  • The prognosis of this disease are correlated with the stage, B symptoms and T cell phenotype.
  • [MeSH-major] Intestinal Neoplasms. Lymphoma, Non-Hodgkin
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Female. Follow-Up Studies. Humans. Lymphoma, B-Cell / drug therapy. Lymphoma, B-Cell / pathology. Lymphoma, B-Cell / surgery. Lymphoma, Large B-Cell, Diffuse / drug therapy. Lymphoma, Large B-Cell, Diffuse / pathology. Lymphoma, Large B-Cell, Diffuse / surgery. Male. Middle Aged. Neoplasm Staging. Prednisone / administration & dosage. Proportional Hazards Models. Remission Induction. Retrospective Studies. Survival Rate. Vincristine / administration & dosage

  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16750023.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


17. Li B, Shi YK, He XH, Zou SM, Zhou SY, Dong M, Yang JL, Liu P, Xue LY: Primary non-Hodgkin lymphomas in the small and large intestine: clinicopathological characteristics and management of 40 patients. Int J Hematol; 2008 May;87(4):375-81

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary non-Hodgkin lymphomas in the small and large intestine: clinicopathological characteristics and management of 40 patients.
  • To investigate the clinicopathological characteristics and optimal treatment modalities of primary non-Hodgkin lymphoma (NHL) in the small and large intestine.
  • Forty patients with primary NHL in the small and large intestine were studied retrospectively.
  • All cases were reclassified according to the World Health Organization (WHO) classification of lymphoma in 2001.
  • Fourteen patients had primary disease in the small intestine, which were all of B-cell origin with diffuse large B-cell lymphoma (DLBCL) diagnosed in 5 of 14 (35.7%) patients and mucosa-associated lymphoid tissue (MALT) lymphoma in 8 of 14 (57.1%) patients.
  • Twenty-five patients had primary colorectal lymphoma, with B-cell origin accounting for 92.0% and T-cell origin for 8.0% of these patients.
  • Compared with surgery alone, post-operation chemotherapy or chemoradiotherapy can significantly improve DLBCL patients' event-free survival (EFS).
  • However, no post-operation treatment modality can improve OS or EFS for patients with MALT lymphoma.
  • B-cell lymphoma is the most common pathological type of intestinal lymphomas.
  • Chemotherapy-containing treatment modality is an effective way to improve intestinal lymphoma patients' EFS, especially for those with DLBCL subtype.
  • [MeSH-major] Intestinal Neoplasms / pathology. Intestinal Neoplasms / therapy. Intestine, Large / pathology. Intestine, Small / pathology. Lymphoma, Non-Hodgkin / pathology. Lymphoma, Non-Hodgkin / therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Female. Humans. Male. Middle Aged. Survival Rate. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Zhonghua Wei Chang Wai Ke Za Zhi. 2006 Nov;9(6):502-5 [17143795.001]
  • [Cites] Histopathology. 2003 Aug;43(2):135-43 [12877728.001]
  • [Cites] Am Surg. 1988 May;54(5):262-6 [3364860.001]
  • [Cites] Med Oncol. 2005;22(1):57-62 [15750197.001]
  • [Cites] Cancer. 1985 Mar 1;55(5):1060-73 [3881161.001]
  • [Cites] Cancer Causes Control. 2005 Sep;16(7):781-7 [16132788.001]
  • [Cites] Gastroenterol Jpn. 1976;11(2):141-7 [789171.001]
  • [Cites] Dig Dis Sci. 2005 Dec;50(12):2243-7 [16416168.001]
  • [Cites] J Clin Oncol. 2005 Oct 1;23(28):7050-9 [16129843.001]
  • [Cites] Gastroenterology. 2000 Nov;119(5):1191-202 [11054376.001]
  • [Cites] Am J Med. 1991 Jan;90(1):77-84 [1702581.001]
  • [Cites] Cancer. 2003 May 15;97(10):2462-73 [12733145.001]
  • [Cites] J Clin Oncol. 2001 Sep 15;19(18):3861-73 [11559724.001]
  • [Cites] Rofo. 1983 Mar;138(3):283-7 [6403420.001]
  • [Cites] Eur J Surg. 1997 Nov;163(11):803-13 [9414040.001]
  • [Cites] Ann Surg. 2004 Jul;240(1):44-50 [15213617.001]
  • [Cites] Leuk Lymphoma. 2004 Sep;45(9):1847-52 [15223645.001]
  • [Cites] Br J Cancer. 1993 Apr;67(4):776-82 [8471435.001]
  • [Cites] Gastroenterology. 1994 Apr;106(4):846-58 [8143991.001]
  • [Cites] Isr Med Assoc J. 2006 Dec;8(12):832-5 [17214096.001]
  • [Cites] Cancer. 1989 Sep 15;64(6):1208-17 [2670184.001]
  • [Cites] Br J Cancer. 1989 Aug;60(2):244-8 [2765374.001]
  • [Cites] Ann Oncol. 2001 Jan;12(1):53-8 [11249049.001]
  • [Cites] Leuk Lymphoma. 2006 Jul;47(7):1253-9 [16923554.001]
  • [Cites] Acta Oncol. 1988;27(1):51-5 [3284553.001]
  • [Cites] Semin Oncol. 1999 Jun;26(3):324-37 [10375089.001]
  • [Cites] Zhonghua Zhong Liu Za Zhi. 2006 Feb;28(2):142-4 [16750023.001]
  • [Cites] Dis Colon Rectum. 2000 Sep;43(9):1277-82 [11005497.001]
  • [Cites] Am J Surg Pathol. 2000 May;24(5):688-93 [10800987.001]
  • [Cites] Med Oncol. 2006;23(2):225-35 [16720923.001]
  • [Cites] Cancer. 2005 Aug 1;104(3):532-40 [15937928.001]
  • [Cites] Cancer. 1978 Aug;42(2):693-707 [354774.001]
  • [Cites] Ann Oncol. 1997 Aug;8(8):727-37 [9332679.001]
  • [Cites] Colorectal Dis. 2006 Sep;8(7):586-91 [16919111.001]
  • [Cites] Cancer. 2000 Jan 15;88(2):286-94 [10640959.001]
  • (PMID = 18409078.001).
  • [ISSN] 0925-5710
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


18. Tamura H, Ogata K, Kondo A, Wakita T, Inami M, Mizuki T, Hyodo H, Shioi Y, Nakamura K, Mitsui K, Tanaka S, Sakamoto C, Dan K: [Double balloon endoscopy as a useful tool for the diagnosis and treatment of four cases of primary small intestinal lymphoma]. Rinsho Ketsueki; 2007 Jun;48(6):510-3
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Double balloon endoscopy as a useful tool for the diagnosis and treatment of four cases of primary small intestinal lymphoma].
  • Primary small intestinal lymphoma (PSIL) is a relatively rare form of non-Hodgkin lymphoma, often complicated by bleeding, obstruction, or perforation of the intestine during the clinical course.
  • The initial diagnosis and management of these complications are often difficult in PSIL, because the small intestine is usually inaccessible in routine endoscopy.
  • Recently, total enteroscopy with a double-balloon method, called double balloon endoscopy (DBE), has been developed for the diagnosis and treatment of small intestinal disorders.
  • We report herein on 4 cases of PSIL (2 diffuse large B-cell lymphomas and 2 follicular lymphomas [FLs]).
  • In these cases, DBE was useful in the diagnosis, decision to perform surgery after assessment of bleeding lesion, and treatment of the intestinal stenosis using enteroscopic balloon dilatation.
  • Combination chemotherapy consisting of anthracycline, cyclophosphamide, vincristine, and prednisolone with rituximab was administered in 3 cases, and all achieved complete remission.
  • More PSIL cases must be analyzed to establish the optimal management of patients with this form of lymphoma.
  • [MeSH-major] Catheterization / methods. Endoscopes, Gastrointestinal. Endoscopy, Gastrointestinal / methods. Intestinal Neoplasms / diagnosis. Intestinal Neoplasms / therapy. Intestine, Small. Lymphoma / diagnosis. Lymphoma / therapy
  • [MeSH-minor] Aged. Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal, Murine-Derived. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Fatal Outcome. Female. Humans. Male. Middle Aged. Prednisolone / administration & dosage. Rituximab. Treatment Outcome. Vincristine / administration & dosage

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17633101.001).
  • [ISSN] 0485-1439
  • [Journal-full-title] [Rinshō ketsueki] The Japanese journal of clinical hematology
  • [ISO-abbreviation] Rinsho Ketsueki
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone; VAP-cyclo protocol
  •  go-up   go-down


19. Gale J, Simmonds PD, Mead GM, Sweetenham JW, Wright DH: Enteropathy-type intestinal T-cell lymphoma: clinical features and treatment of 31 patients in a single center. J Clin Oncol; 2000 Feb;18(4):795-803

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Enteropathy-type intestinal T-cell lymphoma: clinical features and treatment of 31 patients in a single center.
  • PURPOSE: We report the clinical features and treatment of 31 patients with a diagnosis of enteropathy-type intestinal T-cell lymphoma treated at the Wessex Regional Medical Oncology Unit in Southampton between 1979 and 1996 (23 men, eight women).
  • PATIENTS AND METHODS: Patients were identified from our lymphoma database.
  • Details of history, physical examination, staging investigations, treatment, and outcome were taken from patient records.
  • RESULTS: Twelve patients (35%) had a documented clinical history of adult-onset celiac disease, and a further three had histologic features consistent with celiac disease in resected areas of the small bowel not infiltrated with lymphoma.
  • After diagnosis, 24 (77%) of the 31 patients were treated with chemotherapy; the remaining seven had surgical treatment alone.
  • More than half were unable to complete their planned chemotherapy courses, often because of poor nutritional status; 12 patients required enteral or parenteral feeding.
  • A response to initial chemotherapy was observed in 14 patients (complete response, n = 10; partial response, n = 4).
  • Observed complications of treatment were gastrointestinal bleeding, small-bowel perforation, and the development of enterocolic fistulae.
  • Relapses occurred 1 to 60 months from diagnosis in 79% of those who responded to initial therapy.
  • Of the total 31 patients, 26 (84%) have died, all from progressive disease or from complications of the disease and/or its treatment.
  • This, in part, reflects late diagnosis and poor performance status at the time of presentation.
  • The role of salvage treatments and high-dose chemotherapy at relapse is not clear.
  • [MeSH-major] Intestinal Neoplasms / diagnosis. Lymphoma, T-Cell / diagnosis
  • [MeSH-minor] Actuarial Analysis. Adult. Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Celiac Disease / pathology. Disease Progression. Disease-Free Survival. Enteral Nutrition. Female. Follow-Up Studies. Humans. Intestine, Small / pathology. Male. Middle Aged. Neoplasm Recurrence, Local / pathology. Neoplasm Staging. Nutritional Status. Parenteral Nutrition. Physical Examination. Postoperative Complications. Prognosis. Remission Induction. Retrospective Studies. Survival Rate. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10673521.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


20. Souza MJ, Newman SJ, Greenacre CB, Avenell JS, Wall JS, Phillips JC, Fry MM, Donnell RL, Daniel GB: Diffuse intestinal T-cell lymphosarcoma in a yellow-naped Amazon parrot (Amazona ochrocephala auropalliata). J Vet Diagn Invest; 2008 Sep;20(5):656-60

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diffuse intestinal T-cell lymphosarcoma in a yellow-naped Amazon parrot (Amazona ochrocephala auropalliata).
  • A distended proventriculus and diffusely thickened loops of small intestine with irregular luminal surfaces were identified with contrast radiography and contrast computed tomography.
  • A micro positron emission tomography scan was performed with (18)F-fluorodeoxyglucose.
  • Diffuse intestinal T-cell lymphosarcoma was diagnosed based on histopathology and immunohistochemistry of full thickness small intestinal biopsies.
  • The patient was treated with a multidrug chemotherapy protocol with little to no effect.
  • Euthanasia was elected, and intestinal lymphosarcoma was confirmed on histopathology of necropsy intestinal samples; no other organs demonstrated neoplastic infiltration.
  • To the authors' knowledge, no reports are currently available detailing the clinical presentation or diagnosis of diffuse intestinal T-cell lymphosarcoma in any avian species.
  • [MeSH-major] Bird Diseases / pathology. Intestinal Neoplasms / veterinary. Lymphoma, Non-Hodgkin / veterinary. Lymphoma, T-Cell, Cutaneous / veterinary
  • [MeSH-minor] Animals. Euthanasia. Parrots. Positron-Emission Tomography / veterinary. Radiography

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18776105.001).
  • [ISSN] 1040-6387
  • [Journal-full-title] Journal of veterinary diagnostic investigation : official publication of the American Association of Veterinary Laboratory Diagnosticians, Inc
  • [ISO-abbreviation] J. Vet. Diagn. Invest.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


21. Sakakibara T, Kurasawa T, Narumi K, Kamano T, Tsurumaru M: T-cell malignant lymphoma of the ileum causing ileac fistulas: report of a case. Surg Today; 2002;32(6):536-40
MedlinePlus Health Information. consumer health - Intestinal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] T-cell malignant lymphoma of the ileum causing ileac fistulas: report of a case.
  • We herein present a rare case of three fistulas caused by a recurrence of T-cell lymphoma of the ileum.
  • Upper and lower gastrointestinal examinations did not reveal any abnormal findings, but an abdominal aortic aneurysm was diagnosed by computed tomography, and thus was determined to be the source of the pain.
  • The patient was referred to our hospital to undergo a grafting operation; however, a laparotomy performed in July 1997 revealed an unexpected small intestinal tumor, and therefore a partial ileectomy between 15 and 70cm in an oral direction from the terminal ileum was carried out instead.
  • Histopathological and genetic examinations demonstrated diffuse small malignant lymphocytic T-cell lymphomas of the ileum invading all layers.
  • Metastasis of the facial skin and local recurrence were recognized 5 months later, and chemotherapy with THP-COP and ESHAP only resulted in progressive disease.
  • An ileac fistula was found to have formed between the intestine and abdominal wall in March 1998, and the patient died in May 1998.
  • [MeSH-major] Ileal Neoplasms / complications. Intestinal Fistula / etiology. Lymphoma, T-Cell / complications

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12107782.001).
  • [ISSN] 0941-1291
  • [Journal-full-title] Surgery today
  • [ISO-abbreviation] Surg. Today
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 10
  •  go-up   go-down


22. Shiratsuchi M, Suehiro Y, Yoshikawa Y, Ohshima K, Shiokawa S, Nishimura J: Extranodal multiple involvement of enteropathy-type T-cell lymphoma without expression of CC chemokine receptor 7. Int J Hematol; 2004 Jan;79(1):44-7
Hazardous Substances Data Bank. METHYLPREDNISOLONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extranodal multiple involvement of enteropathy-type T-cell lymphoma without expression of CC chemokine receptor 7.
  • Enteropathy-type T-cell lymphoma (ETCL) is a rare extranodal lymphoma that tends to disseminate into the intestines and other extranodal organs.
  • We present a case of ETCL with involvement of the lungs and kidneys and report CC chemokine receptor 7 (CCR7) expression of lymphoma cells.
  • Multiple ulcers and perforations were observed in the small intestine, and partial resection of the ileum was performed.
  • The diagnosis was ETCL with dissemination into the lungs and kidney.
  • Lymphoma cells of the small intestine and in pleural effusion were CD3+, CD4+, CD7+, CD8-, CD25-, CD56-, CD103 +/-, and TIA-1+.
  • Rearrangement of the T-cell receptor beta gene was detected, and human T-lymphotropic virus was not integrated.
  • Combination chemotherapy did not result in a sustained response.
  • The results for CCR7 expression of lymphoma cells in the lung and pleural effusion were negative.
  • Therefore we concluded that lymphoma cells did not migrate into the lymph nodes but instead spread into the extranodal organs.
  • [MeSH-major] Lymphoma, T-Cell / pathology
  • [MeSH-minor] Aged. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cell Movement. Cisplatin / administration & dosage. Cyclophosphamide / administration & dosage. Cytarabine / administration & dosage. Doxorubicin / administration & dosage. Etoposide / administration & dosage. Fatal Outcome. Humans. Immunophenotyping. Intestinal Mucosa / pathology. Intestinal Neoplasms / pathology. Intestine, Small / pathology. Lymph Nodes / pathology. Male. Methylprednisolone / administration & dosage. Neoplasm Invasiveness. Neoplastic Stem Cells / pathology. Organ Specificity. Pleural Effusion / pathology. Prednisone / administration & dosage. Receptors, CCR7. Receptors, Chemokine. T-Lymphocyte Subsets / pathology. Vincristine / administration & dosage. Viscera / pathology

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Pathol. 1992 Dec;141(6):1361-71 [1466400.001]
  • [Cites] Br J Haematol. 2000 May;109(2):258-66 [10848810.001]
  • [Cites] J Clin Oncol. 2000 Feb;18(4):795-803 [10673521.001]
  • [Cites] Blood. 2000 Jan 1;95(1):30-8 [10607681.001]
  • [Cites] Cell. 1999 Oct 1;99(1):23-33 [10520991.001]
  • [Cites] J Biol Chem. 1997 Aug 1;272(31):19518-24 [9235955.001]
  • [Cites] J Biol Chem. 1997 May 23;272(21):13803-9 [9153236.001]
  • [Cites] Eur J Immunol. 2000 Mar;30(3):819-26 [10741397.001]
  • [Cites] Nature. 1999 Oct 14;401(6754):708-12 [10537110.001]
  • [Cites] Blood. 2002 Apr 15;99(8):2977-84 [11929789.001]
  • [Cites] Blood. 2003 Apr 1;101(7):2473-5 [12642342.001]
  • [Cites] Immunity. 2001 Apr;14(4):377-86 [11336683.001]
  • (PMID = 14979477.001).
  • [ISSN] 0925-5710
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / CCR7 protein, human; 0 / Receptors, CCR7; 0 / Receptors, Chemokine; 04079A1RDZ / Cytarabine; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; Q20Q21Q62J / Cisplatin; VB0R961HZT / Prednisone; X4W7ZR7023 / Methylprednisolone; EPOCH protocol; ESAP protocol
  •  go-up   go-down


23. Chen CQ, Yin L, Peng CH, Zhao R, Chen GM, Zhou HJ, Li HW: [Primary non-Hodgkin lymphoma of small bowel: a clinical analysis of 34 cases]. Zhonghua Wei Chang Wai Ke Za Zhi; 2007 May;10(3):249-52
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Primary non-Hodgkin lymphoma of small bowel: a clinical analysis of 34 cases].
  • OBJECTIVE: To study the clinical characteristics,treatment and prognosis of primary non-Hodgkin's lymphoma of small bowel.
  • METHODS: The records of 34 patients with a confirmed diagnosis of primary non-Hodgkin's lymphoma of small bowel, registered between Jan.
  • RESULTS: Twenty-seven patients had B-cell lymphoma and 7 had T-cell lymphoma of the small bowel.
  • The major symptoms included abdominal pain and intestinal obstruction.
  • According to Ann Arbor staging classification, 22 patients belonged to stage I~II, including 20 cases of B-cell lymphoma and 2 cases of T-cell lymphoma, and 12 patients belonged to stage III~IV, including 7 cases of B-cell lymphoma and 5 cases of T-cell lymphoma.
  • Compared with T-cell lymphoma patients, B-cell lymphoma patients had lower lymphoma stages (P<0.05).
  • Fourteen patients were treated with six cycles of cyclophosphamide, doxorubicin, vincristine, and prednisolone (CHOP) chemotherapy, and 8 patients were treated with Rituximab at the same time.
  • T-cell lymphoma patients were more often treated with emergent operation than B-cell lymphoma patients would (P<0.05).
  • It happened more frequently that B-cell lymphoma patients reached complete remission and their accumulative survival rate was longer than T-cell lymphoma patients did (P<0.05).
  • CONCLUSION: Patients with stages I and II B-cell lymphoma of small bowel respond well to surgery and chemotherapy, and the treatment and prognosis of patients with T-cell lymphoma of small bowel are unsatisfactory.
  • [MeSH-major] Intestinal Neoplasms / diagnosis. Intestine, Small / pathology. Lymphoma, Non-Hodgkin / diagnosis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Lymphoma, B-Cell / diagnosis. Lymphoma, B-Cell / pathology. Lymphoma, T-Cell / diagnosis. Lymphoma, T-Cell / pathology. Male. Middle Aged. Neoplasm Staging. Prognosis. Retrospective Studies

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17520384.001).
  • [ISSN] 1671-0274
  • [Journal-full-title] Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  • [ISO-abbreviation] Zhonghua Wei Chang Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


24. Fukushima T, Sawaki T, Shimoyama K, Karasawa H, Masaki Y, Kawabata H, Ogawa N, Wano Y, Hirose Y, Sugai S, Sutoh H, Itoh H, Kojima Y: [Successful treatment with etoposide by oral administration for recurrence of gastric diffuse large B-cell lymphoma after surgical resection--a case report]. Gan To Kagaku Ryoho; 2005 Feb;32(2):251-3
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Successful treatment with etoposide by oral administration for recurrence of gastric diffuse large B-cell lymphoma after surgical resection--a case report].
  • A 64-year-old woman, who had been treated for gastric diffuse large B-cell lymphoma (DLBCL) by total gastrectomy and received 3 courses of CHOP therapy at 61 years of age, was diagnosed with recurrence of DLBCL in the small intestine.
  • After the small intestinal tumor was resected, multiple metastases were found in the liver.
  • Because intensive chemotherapy was difficult for her poor performance status, 50 mg of etoposide daily by oral was administered for 21 consecutive days.
  • After one course of chemotherapy, liver metastases and lymph node swelling almost disappeared without severe adverse effects, and after five courses she achieved complete remission.
  • This case report suggests that oral etoposide therapy is useful for gastrointestinal DLBCL which has metastasized to the liver.
  • [MeSH-major] Antineoplastic Agents, Phytogenic / administration & dosage. Etoposide / administration & dosage. Ileal Neoplasms / drug therapy. Lymphoma, B-Cell / drug therapy. Lymphoma, Large B-Cell, Diffuse / drug therapy. Stomach Neoplasms / pathology
  • [MeSH-minor] Administration, Oral. Combined Modality Therapy. Female. Gastrectomy. Humans. Liver Neoplasms / secondary. Middle Aged. Remission Induction


25. van der Veer WM, Hekmat H, Mulder CJ, Jacobs MA: [Double-balloon enteroscopy for the diagnosis and treatment of patients with unexplained gastrointestinal blood loss]. Ned Tijdschr Geneeskd; 2007 Sep 22;151(38):2077-81

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Double-balloon enteroscopy for the diagnosis and treatment of patients with unexplained gastrointestinal blood loss].
  • DBE is a relatively new endoscopic technique that allows high-resolution visualisation of the entire small intestine with full endoscopic instrumentation.
  • The 56-year-old woman had coeliac disease and an enteropathy-associated T-cell lymphoma with stenoses over approximately 150 cm of bowel length.
  • She was given chemotherapy and responded well.
  • The 57-year-old woman suffered from Rendu-Osler-Weber syndrome with multiple angiodysplasias in the small intestine.
  • She was treated 5 times with argon plasma coagulation during DBE, for more than 40 angiodysplasias, and thereafter no longer needed blood transfusions.
  • During DBE, multiple metastases of a melanoma in the small intestine were found and tattooed.
  • DBE has proven to be a good diagnostic and therapeutic tool in the management of small intestinal diseases.
  • [MeSH-major] Endoscopy, Gastrointestinal / methods. Intestinal Diseases / diagnosis. Intestinal Diseases / surgery. Intestine, Small / surgery
  • [MeSH-minor] Aged. Angiodysplasia / diagnosis. Angiodysplasia / surgery. Celiac Disease / diagnosis. Celiac Disease / surgery. Female. Gastrointestinal Hemorrhage / diagnosis. Gastrointestinal Hemorrhage / surgery. Gastrointestinal Neoplasms / diagnosis. Gastrointestinal Neoplasms / surgery. Humans. Male. Middle Aged. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Ned Tijdschr Geneeskd. 2007 Sep 22;151(38):2087-93 [17948823.001]
  • (PMID = 17948821.001).
  • [ISSN] 0028-2162
  • [Journal-full-title] Nederlands tijdschrift voor geneeskunde
  • [ISO-abbreviation] Ned Tijdschr Geneeskd
  • [Language] dut
  • [Publication-type] Case Reports; Comment; English Abstract; Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


26. Yoneda K, Takahashi H, Abe Y, Inamori M, Kato S, Uchiyama T, Iida H, Mawatari H, Hosono K, Endo H, Nozaki Y, Akiyama T, Fujita K, Yoneda M, Kobayashi N, Kirikoshi H, Kubota K, Saito S, Nakajima A: A mucosa-associated lymphoid tissue (MALT) lymphoma of the small intestine that was difficult to diagnose endoscopically. Endoscopy; 2010;42 Suppl 2:E175
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A mucosa-associated lymphoid tissue (MALT) lymphoma of the small intestine that was difficult to diagnose endoscopically.
  • [MeSH-major] Intestinal Neoplasms / diagnosis. Intestine, Small / pathology. Lymphoma, B-Cell, Marginal Zone / diagnosis
  • [MeSH-minor] Aged. Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal, Murine-Derived. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biopsy. Colonoscopy. Cyclophosphamide / therapeutic use. Diagnosis, Differential. Doxorubicin / therapeutic use. Helicobacter Infections / diagnosis. Helicobacter Infections / drug therapy. Helicobacter pylori. Humans. Male. Prednisolone / therapeutic use. Rituximab. Tomography, X-Ray Computed. Vincristine / therapeutic use

  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20560120.001).
  • [ISSN] 1438-8812
  • [Journal-full-title] Endoscopy
  • [ISO-abbreviation] Endoscopy
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone; VAP-cyclo protocol
  •  go-up   go-down






Advertisement